spacer
home > pmps > winter 2019 > contamination control
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Contamination Control

Pharmaceutical companies may unwittingly be putting production processes at risk of contamination by fitting mechanical seals made from unsafe materials. Seals which fail to comply with industry regulations might slip through the net, and the solution to avoiding the contamination risk could actually be very simple.

Mechanical seals have a key function in pharma production processes. However, because they are regarded as component parts, they are often overlooked when it comes to compliance with FDA regulations and pharma current Good Manufacturing Practice (cGMP).

Crossover between the pharma, biopharmaceutical, and food and beverage sectors is routine – the use of the dairy by-product β-lactose as an excipient is a typical example. Therefore, it makes sense that both cGMP and the regulations governing food contact materials (FCMs) must apply equal weight in both sectors.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
John Smiddy is the European Regional Business Development and Technical Support Director for AESSEAL. Since joining the company in 1995, he has worked in many chemical and pharma plants, solving complex sealing problems and offering solutions to extend mechanical seal life. John has extensive knowledge of the chemical, pharma, and food and beverage industries and of the regulation around pharma production. He is a leader within AESSEAL, promoting mechanical seal standards for this sector.
spacer
John Smiddy
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Blockbuster Drugs Need Blockbuster Components

West Pharmaceutical Services, Inc.

Many of the world’s blockbuster drugs are now delivered via a prefilled syringe system or auto-injector. To ensure patient safety, pharmaceutical manufacturers need high-quality components that feature reduced particulates and ensure consistency of delivery while fitting the changing needs of higher-volume delivery systems.
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement